Back

SGLT2 inhibitors in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis

9 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: TAVI and aortic stenosis: imaging, prediction, outcomes Intervention HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Luigi Spadafora

Sapienza University of Rome, Latina (Italy)

6 More presentations in this session

Presentation thumbnail
Association between CT-derived extracellular volume and echocardiographic parameters in severe aortic stenosis
Doctor A. Lobo (Vila Nova de Gaia, PT)
Abstract Slides
Presentation thumbnail
What drives mortality in paradoxical low-flow, low-gradient aortic stenosis?
Doctor M. Moura (Porto, PT)
Abstract Slides
Presentation thumbnail
Acceleration time as a predictor of true severity in low-flow low-gradient aortic stenosis: insights from dobutamine stress echocardiography
Doctor F. Rodrigues Santos (Viseu, PT)
Abstract Slides
Presentation thumbnail
Transcatheter versus surgical aortic valve replacement in bicuspid aortic stenosis: baseline characteristics and early clinical outcomes
Doctor C. Santos Jorge (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Valve sizing in TAVR: avoiding over- and under-sizing
Doctor F. Nascimento Ferreira (Lisbon, PT)
Abstract Slides

Access the full session

Session thumbnail
TAVI and aortic stenosis: imaging, prediction, outcomes

The Event

Event poster

Heart Failure 2026

9 May 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 Inhibitors in patients with cancers
20 June 2025
thumbnail
Congress Presentation
Clinical outcomes of patients undergoing percutaneous coronary intervention and transcatheter aortic valve implantation versus coronary artery bypass grafting and surgical aortic valve replacement
1 September 2025
thumbnail
Congress Presentation
Impact of TAVR on GDMT in patients with severe aortic stenosis and HFrEF
1 September 2025
thumbnail
Congress Presentation
DapaTAVI: dapagliflozin in patients undergoing transcatheter aortic valve implantation
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources